Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Azafaros

News headline image
Azafaros Further Strengthens Its Board of Directors With Appointment of Biotech Entrepreneur Dr. Thierry Abribat
From Azafaros
Via Business Wire
News headline image
Azafaros Announces Initiation of two Global Phase 3 studies with Nizubaglustat in Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses, respectively
From Azafaros
Via Business Wire
News headline image
Azafaros to Present at BIO International Convention 2025 Following Successful €132M Series B Financing
From Azafaros
Via Business Wire
News headline image
Azafaros Secures € 132M in Oversubscribed Series B Financing to Advance Phase 3 Clinical Programs of Innovative Therapies in Lysosomal Storage Disorders
From Azafaros
Via Business Wire
News headline image
Positive Niemann-Pick disease type C (NPC) and GM2 gangliosidosis data from nizubaglustat Phase 2 RAINBOW study conducted by Azafaros presented at major metabolic disease conference
From Azafaros
Via Business Wire
News headline image
Azafaros Announces Enrollment of First Patient in Phase 2 RAINBOW Study Evaluating AZ-3102 in GM2 and NP-C Patients
From Azafaros
Via Business Wire
News headline image
Azafaros Appoints Chief Operating Officer and Head of Finance
From Azafaros
Via Business Wire
News headline image
Azafaros Receives Additional Regulatory Designations for AZ-3102 from FDA, EMA and MHRA
From Azafaros
Via Business Wire
News headline image
Azafaros Receives FDA's IND Clearance and Fast Track Designation for Lead Asset AZ-3102
From Azafaros
Via Business Wire
News headline image
Azafaros Announces FDA Grant of Orphan Drug Designation for AZ-3102 in the Treatment of Niemann-Pick Disease
From Azafaros
Via Business Wire
News headline image
Azafaros Presents Positive Clinical and Preclinical Data Supporting Development of Lead Compound AZ-3102 in Lysosomal Storage Disorders at the 18th Annual WORLDSymposium™ Conference
From Azafaros
Via Business Wire
News headline image
Azafaros Receives FDA Orphan Drug Designation for AZ-3102 in GM2 Gangliosidosis
From Azafaros
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.